USPTO Examiner ABDALHAMEED MANAHIL MIRGHANI ALI - Art Unit 1622

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18882644QUINOLINONE AMIDE COMPOUNDS AND USES THEREOFSeptember 2024April 2025Allow811NoNo
18807584FORMULATIONS OF AMINOPENICILLIN AND METHODS FOR SOLUBILIZING AMINOPENICILLINAugust 2024May 2025Allow920YesNo
18723881SALT FORM AND CRYSTAL FORM OF TETRAHYDROCYCLOHEPTA INDAZOLE COMPOUNDAugust 2024May 2025Allow1010YesNo
18832280BENZOISOTHIAZOLE AND BENZOISOXAZOLE COMPOUNDS FOR THE TREATMENT OF MENTAL DISORDERSJuly 2024February 2025Allow700YesNo
18743025ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOFJune 2024March 2025Allow920NoNo
18420250METHOD OF TREATING ALZHEIMER�S DISEASEJanuary 2024October 2024Abandon910YesNo
18418030METHODS OF USE OF EMULSION FORMULATIONS OF AN NK-1 RECEPTOR ANTAGONISTJanuary 2024July 2024Allow610NoNo
18408486METHODS OF USE OF EMULSION FORMULATIONS OF AN NK-1 RECEPTOR ANTAGONISTJanuary 2024June 2024Allow510NoNo
18483401TREATMENT OF FRAGILE X SYNDROME WITH CANNABIDIOLOctober 2023April 2025Abandon1910NoNo
18232651METHODS OF SYNTHESIZING SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDSAugust 2023April 2025Allow2010NoNo
18366113PIPERIDINE UREA DERIVATIVES AS SOLUBLE EPOXIDE HYDROLASE INHIBITORSAugust 2023July 2024Allow1100YesNo
18216089LAURETH-4 CONTAINING TOPICAL FORMULATIONSJune 2023May 2024Allow1000YesNo
18331348PYRIDINYL SUBSTITUTED OXOISOINDOLINE COMPOUNDSJune 2023September 2024Abandon1510NoNo
18185711Anti-oxidant CompositionsMarch 2023August 2024Allow1720YesNo
18173207LPXC INHIBITOR, FORMULATIONS, AND USES THEREOFFebruary 2023April 2024Abandon1410NoNo
17985738COMBINATION TREATMENT OF LIVER DISORDERSNovember 2022May 2025Abandon3030NoNo
17979577METHODS OF USE OF EMULSION FORMULATIONS OF AN NK-1 RECEPTOR ANTAGONISTNovember 2022June 2023Allow810NoNo
18051654CRYSTALLINE FORMS OF A MAGL INHIBITORNovember 2022July 2024Allow2011NoNo
18050139PYRIDIZIN-3(2H)-ONE DERIVATIVESOctober 2022October 2024Abandon2420NoNo
17884933COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITYAugust 2022September 2024Allow2511YesNo
17874564PHARMACEUTICAL COMPOUNDSJuly 2022December 2022Allow510NoNo
17872721METHODS FOR THE TREATMENT OF CANCER USING 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREAJuly 2022May 2025Allow3431YesNo
17837851LIPID CRYSTALLINE COMPOSITIONS WITH ENHANCED STABILITY FOR TOPICAL DELIVERY OF ACTIVE AGENT COMBINATIONSJune 2022April 2025Abandon3430YesNo
17664184METHOD FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS USING QUERCETIN-CONTAINING COMPOSITIONSMay 2022April 2025Allow3530YesNo
17748451METHOD OF TREATING ALZHEIMER'S DISEASEMay 2022March 2024Abandon2210NoNo
17744537SOLID FORMS OF A MODULATOR OF HEMOGLOBINMay 2022July 2023Allow1510NoNo
17736908SHP2 INHIBITOR MONOTHERAPY AND USES THEREOFMay 2022April 2025Allow3530YesNo
17733488EXPANDED DOSAGE REGIMENS FOR INTEGRIN INHIBITORSApril 2022May 2025Abandon3740YesNo
17725398METHODS OF TREATING NON-HODGKIN LYMPHOMA USING 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONEApril 2022December 2024Abandon3230NoNo
17720450PIPERIDINE UREA DERIVATIVES AS SOLUBLE EPOXIDE HYDROLASE INHIBITORSApril 2022January 2024Allow2130YesNo
17713472Combination Therapies Using PRMT5 Inhibitors for the Treatment of CancerApril 2022August 2024Allow2821YesNo
17713598PYRIDINYL SUBSTITUTED OXOISOINDOLINE COMPOUNDSApril 2022April 2023Allow1301NoNo
17690663CHEWABLE FORMULATIONSMarch 2022November 2023Abandon2011NoNo
17690094Orally Active Melanocortin Receptor-4 CompoundsMarch 2022June 2025Allow3930YesNo
17687525TREATMENT OF COPPER DISORDERSMarch 2022September 2024Abandon3121NoNo
17677437PARENTERAL COMPOSITIONS COMPRISING METHYLENE BLUEFebruary 2022November 2024Allow3340YesNo
17677408SOLUTION FORMULATIONS OF CX-011February 2022January 2024Allow2221NoNo
17672670EFFECTS OF LYSERGIC ACID DIETHYLAMIDE (LSD) AND OF LSD ANALOGS TO ASSIST PSYCHOTHERAPY FOR GENERALIZED ANXIETY DISORDER OR OTHER ANXIETY NOT RELATED TO LIFE-THREATENING ILLNESSFebruary 2022March 2025Abandon3760YesNo
17671714DOSAGE REGIMENS FOR PARP7 INHIBITORSFebruary 2022October 2023Abandon2010NoNo
17670712ABIRATERONE PRODRUGSFebruary 2022January 2024Allow2311YesNo
17649938CANNABINOID FORMULATION: PRODUCTION METHOD AND USEFebruary 2022October 2023Allow2010NoNo
17549227METHODS FOR TREATING CILIATED CAVITIESDecember 2021February 2023Allow1400NoNo
17534771ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORSNovember 2021May 2024Abandon2920NoNo
17533931METHODS OF SYNTHESIZING SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDSNovember 2021May 2023Allow1710NoNo
17515758ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOFNovember 2021March 2025Abandon4111NoNo
17451462BICYCLIC COMPOUNDSOctober 2021December 2023Allow2620NoNo
17438413Compounds as Inhibitors of Macrophage Migration Inhibitory FactorSeptember 2021March 2025Abandon4201NoNo
17458797THIENOPYRIMIDINONE NMDA RECEPTOR MODULATORS AND USES THEREOFAugust 2021January 2023Allow1600NoNo
17406771AQUEOUS, ROOM-TEMPERATURE STABLE ROCURONIUM COMPOSITIONAugust 2021March 2024Abandon3121NoNo
17443699LAURETH-4 CONTAINING TOPICAL FORMULATIONSJuly 2021May 2023Allow2220YesNo
17300457Formulations and methodsJuly 2021January 2024Abandon3120NoNo
17360781TREATMENT OF FRAGILE X SYNDROME WITH CANNABIDIOLJune 2021December 2023Abandon3020NoNo
17311560Crystalline Forms of 1-[(3R,4S)-4-Cyanotetrahydropyran-3-YL]-3-[(2-Fluoro-6-Methoxy-4-Pyridyl)Amino]Pyrazole-4-CarboxamideJune 2021February 2024Allow3300YesNo
17339415PHARMACEUTICAL COMPOSITIONS FOR INTRAVENOUS INFUSION IN PLASTIC BAGS WITH REDUCED ADSORPTION ON BAG MEMBRANEJune 2021June 2023Abandon2410NoNo
17336059MITOGEN-ACTIVATED PROTEIN KINASE KINASE (MEK) DEGRADATION COMPOUNDS AND METHODS OF USEJune 2021March 2024Allow3311NoNo
17294860AQUEOUS SOLUTIONS OF POORLY SOLUBLE ACTIVE INGREDIENTS USING POLYALKYOXYLATED AMINO ALCOHOLSMay 2021March 2025Allow4621NoYes
17293970LOX INHIBITORSMay 2021June 2025Abandon4911NoNo
17313679METHODS OF MANUFACTURING A BIFUNCTIONAL COMPOUND, ULTRAPURE FORMS OF THE BIFUNCTIONAL COMPOUND, AND DOSAGE FORMS COMPRISING THE SAMEMay 2021July 2023Allow2611YesNo
17306005CO-CRYSTALS OF SODIUM BENZOATE AND USES THEREOFMay 2021March 2023Allow2310NoNo
17243706TABLET CONTAINING ANTITUMOR AGENTApril 2021October 2024Abandon4210NoNo
17242185Therapeutic Thiazine Dye Compositions and Methods of UseApril 2021October 2024Abandon4221NoYes
17287907CRYSTALLINE FORMS OF POTASSIUM CHANNEL MODULATORSApril 2021January 2024Allow3300YesNo
17223507METHODS AND COMPOSITIONS FOR INHIBITING MUSCLE WASTINGApril 2021June 2023Abandon2611NoNo
17280620INFIGRATINIB FOR TREATMENT OF FGFR3-RELATED SKELETAL DISEASES DURING PREGNANCYMarch 2021April 2024Abandon3630YesNo
17210899METHODS OF TREATING A SUBJECT HAVING AN INFECTIOUS DISEASEMarch 2021May 2023Abandon2501NoNo
17211025LPXC INHIBITOR, FORMULATIONS, AND USES THEREOFMarch 2021April 2023Abandon2510NoNo
17208043ETORICOXIB SOLVATES AND PREPARATION METHOD THEREOFMarch 2021March 2023Allow2411NoNo
17277475COMBINATIONS OF TGF-BETA INHIBITORS AND CDK INHIBITORS FOR CANCER TREATMENTSMarch 2021June 2024Abandon3910NoNo
17275555PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NONALCOHOLIC FATTY LIVER DISEASE, CONTAINING GPR119 LIGAND AS ACTIVE INGREDIENTMarch 2021August 2024Allow4120YesNo
17275176COMBINATION THERAPIESMarch 2021September 2024Allow4230YesNo
17275178COMBINATION THERAPIESMarch 2021September 2024Allow4330YesNo
17180593METHODS OF USE OF EMULSION FORMULATIONS OF AN NK-1 RECEPTOR ANTAGONISTFebruary 2021September 2023Allow3110NoNo
17269569Arginase Inhibitors and Methods of Use thereofFebruary 2021December 2023Allow3400YesNo
17269244ADAMANTANYL-SUBSTITUTED BENZAMIDE COMPOUNDS AND THEIR USE AS P2X7 RECEPTOR ANTAGONISTSFebruary 2021May 2024Abandon3930NoNo
17268049COMBINATION THERAPYFebruary 2021October 2023Abandon3210NoNo
172664332-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASESFebruary 2021August 2024Allow4321YesNo
17168158BICYCLIC PYRIDONE LACTAMS AND METHODS OF USE THEREOFFebruary 2021July 2024Allow4110NoNo
17264882SUBSTITUTED BENZAMIDES AND THEIR USE IN THERAPYFebruary 2021May 2024Abandon4010NoNo
17262586NOVEL TRICYCLIC COMPOUNDS AS BCR-ABL INHIBITORSJanuary 2021January 2024Allow3600YesNo
17262170PIPERAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASEJanuary 2021December 2023Allow3400YesNo
17260592NOVEL COMPOUND ISOLATED FROM CERVI PARVUM CORNU, AND PHARMACEUTICAL USES THEREOFJanuary 2021March 2025Abandon5020NoNo
17149901CONVERGENT SYNTHESIS OF POZIOTINIB DERIVATIVEJanuary 2021June 2023Abandon2910NoNo
17149244BICYCLIC HETEROCYCLES AS FGFR INHIBITORSJanuary 2021February 2024Allow3721YesNo
17260188METHODS OF TREATING RENAL DISEASEJanuary 2021June 2024Abandon4110NoNo
17258913USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERSJanuary 2021October 2024Allow4530YesNo
17257738PROCESS FOR THE PRODUCTION OF ARYLAMINESJanuary 2021August 2024Abandon4420NoNo
17138214METHODS OF TREATING AND PREVENTING NEURODEGENERATIVE DISEASES WITH HGF ACTIVATING COMPOUNDSDecember 2020September 2024Abandon4531NoNo
17120040SURFACTANTS FOR USE IN HEALTHCARE PRODUCTSDecember 2020October 2022Allow2210NoNo
17251621BIFUNCTIONAL MOLECULES FOR TARGETING UCHL5December 2020March 2025Abandon5131NoNo
17058982HIGHLY POTENT TACC3 INHIBITOR AS A NOVEL ANTICANCER DRUG CANDIDATENovember 2020November 2022Allow2410NoNo
17054706TAXANE-LIPID-POLYSACCHARIDE DUAL CONJUGATES, PREPARATION METHODS THEREOF AND USES THEREOFNovember 2020January 2025Allow5041YesNo
170887189-Aminomethyl Minocycline Compounds And Use Thereof In Treating Community-Acquired Bacterial Pneumonia (CABP)November 2020March 2024Abandon4110NoNo
16974157EYE DROPS WITH CITRIC ACID AS THE SOLE ACTIVE INGREDIENTOctober 2020December 2023Abandon3750NoNo
17047992TUMOR ABLATION USING LOW-INTENSITY ULTRASOUND AND SOUND EXCITABLE DRUGOctober 2020January 2024Allow3910NoNo
17047132CHLOROQUINE-BASED MATERIALS FOR THE TREATMENT OF DISEASESOctober 2020May 2024Abandon4310NoNo
17035611METHODS OF USE OF CYCLOPAMINE ANALOGSSeptember 2020October 2022Allow2510NoNo
17040159PIPERIDINE COMPOUNDS AS COVALENT MENIN INHIBITORSSeptember 2020October 2023Abandon3710NoNo
17024799MEANS TO FACILITATE FOOD INTAKE AND FOOD RETENTIONSeptember 2020November 2023Allow3820NoNo
16982517COMPOUND WHICH INHIBITS TELOMERE-BINDING PROTEIN, AND TELOMERE-BINDING PROTEIN INHIBITOR CONTAINING SAMESeptember 2020August 2023Allow3500NoNo
16931128TREATMENT OF IRRITABLE BOWEL AND INFLAMMATORY BOWEL DISEASEJuly 2020March 2024Abandon4421NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ABDALHAMEED, MANAHIL MIRGHANI ALI.

Strategic Value of Filing an Appeal

Total Appeal Filings
4
Allowed After Appeal Filing
1
(25.0%)
Not Allowed After Appeal Filing
3
(75.0%)
Filing Benefit Percentile
30.3%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 25.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner ABDALHAMEED, MANAHIL MIRGHANI ALI - Prosecution Strategy Guide

Executive Summary

Examiner ABDALHAMEED, MANAHIL MIRGHANI ALI works in Art Unit 1622 and has examined 99 patent applications in our dataset. With an allowance rate of 53.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 33 months.

Allowance Patterns

Examiner ABDALHAMEED, MANAHIL MIRGHANI ALI's allowance rate of 53.5% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by ABDALHAMEED, MANAHIL MIRGHANI ALI receive 1.73 office actions before reaching final disposition. This places the examiner in the 50% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by ABDALHAMEED, MANAHIL MIRGHANI ALI is 33 months. This places the examiner in the 26% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +41.0% benefit to allowance rate for applications examined by ABDALHAMEED, MANAHIL MIRGHANI ALI. This interview benefit is in the 90% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 26.3% of applications are subsequently allowed. This success rate is in the 33% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 37.5% of cases where such amendments are filed. This entry rate is in the 49% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 92% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 84% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 57.1% are granted (fully or in part). This grant rate is in the 72% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.